Skip to main content

Cat designer declares war

The less-than-reputable entrepreneur at the helm of a company peddling hypo-allergenic cats is under scrutiny again -- this time for fraudulent "designer cats." But now he's taking the offensive by making allegations against journalists who have covered his company. In January of last year, The Scientist staff writer Kerry Grens investigated a company called Allerca that claimed to have created the world's first hypoallergenic cat. Grens uncovered a string of shady dealings and questionable

Written byAndrea Gawrylewski
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
The less-than-reputable entrepreneur at the helm of a company peddling hypo-allergenic cats is under scrutiny again -- this time for fraudulent "designer cats." But now he's taking the offensive by making allegations against journalists who have covered his company. In January of last year, The Scientist staff writer Kerry Grens investigated a company called Allerca that claimed to have created the world's first hypoallergenic cat. Grens uncovered a string of shady dealings and questionable science associated with the company, including the fact that its founder, Simon Brodie, had served two and a half years in jail for fraud. Read Grens' full story linkurl:here;https://www.the-scientist.com/2007/1/1/32/1/ and a follow-up story linkurl:here.;https://www.the-scientist.com/blog/display/54020/ Last month, San Diego Union-Tribune staff writer Penni Crabtree was investigating the Dutch seizure of three exotic cats that had been sold for about $40,000 by a U.S. company claiming to make designer cats. That company, known as LifeStyle Pets, happens to be an offshoot company of Allerca. The three seized cats were supposed to be a special mixed breed of "exotic" cats, called Ashera (you can read Crabtree's full story linkurl:here;https://www.signonsandiego.com/news/business/biotech/20080205-9999-1b5cats.html ). Over the course of Crabtree's reporting for the story, allegations emerged that the seized cats were not in fact a specially bred mix but just Savannah F1 cats, purchased from a breeder in Pennsylvania. On January 24, Crabtree called and Emailed Brodie for a response to the allegations. Instead of returning calls or Emails, the next day Brodie issued a press release that was picked up by Mass Media, a distribution newswire (read the release from Brodie's Web site linkurl:here;https://www.simonbrodie.com/NsPdf.PDF ). The press release accused Crabtree of accepting money from a competitive pet product company, Idexx Laboratories, in exchange for giving Cyntegra -- another of Brodie's pet companies -- bad press. According to the release, Crabtree is being investigated as part of a lawsuit that Cyntegra is pursuing against Idexx. The release also stated that Grens was being investigated for accepting money from Idexx. Idexx did not return two calls for comment. Crabtree told The Scientist that these accusations are ridiculous. Grens (now senior science reporter at WHYY in Philadelphia) wrote in an Email to The Scientist that she had never interacted with or spoke to anyone at Idexx, never accepted money from them, and was not aware that she was being investigated by Brodie. In response to the press release, Union-Tribune attorney Scott Wahrenbrock sent a letter to both Brodie and Mass Media demanding a retraction. Brodie did not respond, but privately sent out the press release again to hundreds of reporters, Wahrenbrock told The Scientist. He added that Mass Media linkurl:removed;https://www.mmdnewswire.com/despite-subpoen-2823.html Brodie's press release from their Web site and have assured Wahrenbrock that the retraction letter written by the Union-Tribune will be posted there within 24 hours. In a copy of the retraction letter Wahrenbrock sent to The Scientist, which you can read linkurl:here,;https://www.the-scientist.com/supplementary/pdf/54284/UnionTrib_Retract.pdf Wahrenbrock discounts most of the claims made by Brodie, in particular, that Crabtree accepted money to discredit a local businessman (Brodie), and that Crabtree is being investigated for taking money from a rival pet company. In response to a request for comment, Brodie wrote in an Email: "We will not be posting a retraction. I can only presume Mass Media is posting a retraction because they have been threatened by the [Union-Tribune's] attorneys (this is a fact), and not because they want to -- so much for free speech." He refused to provide any evidence against Grens, saying that it is in the hands of his investigators. He also refused to say who his investigators and attorneys are. "I don't know if anybody believes anything he says," Wahrenbrock said. But "he does bilk people out of money."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Improving rAAV Production for Viral Vector Manufacturing

Improving rAAV Production for Viral Vector Manufacturing

cytiva logo
Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Advancing Respiratory Immunity Through Tissue-Resident Memory T Cell Research

Miltenyi
Scientist holding a clear 384-well PCR microplate in a laboratory

What Dictates PCR Success Before Amplification Begins?

Integra Logo
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems

Products

Sino Biological Logo

Sino Biological Launches European Newsletter Campaign with Exclusive Welcome Gifts

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo